SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has appointed veteran medical technology finance executive Sarah M. Romano as chief financial officer, effective August 3, 2026. Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised more than $100 million during her career. The appointment comes as SS Innovations continues pursuing U.S. FDA clearance for its SSi Mantra surgical robotic system while expanding internationally.
Romano most recently served as CFO at Vicarious Surgical, another developer of robotic surgical technologies, where she oversaw financial and operational initiatives designed to reduce cash burn and strengthen the company’s balance sheet. Her expertise in capital markets and medtech finance is expected to be instrumental as SS Innovations advances its regulatory initiatives and broadens commercialization of the SSi Mantra platform. The company is preparing for U.S. Food and Drug Administration review (https://nnw.fm/yY4UM).
In parallel with its regulatory efforts, SS Innovations recently graduated the inaugural class of its SS International Centre for Robotics Surgery (SSICRS) cardiac robotic surgery training program. The program welcomed 33 healthcare professionals from seven countries, underscoring the company’s emphasis on surgeon education alongside technology deployment. This training initiative is critical to ensuring that surgeons are proficient in using the SSi Mantra system, which is designed to enhance precision and outcomes in minimally invasive surgery.
The global expansion of SS Innovations is gaining pace as the company seeks to establish the SSi Mantra as a competitive alternative to established robotic surgery systems. By combining technological innovation with comprehensive training programs, SS Innovations aims to address both the hardware and human factors necessary for successful adoption of robotic surgery. The appointment of Romano signals a strategic focus on financial discipline and capital management to support these growth objectives.
Investors and industry observers will be watching closely as SS Innovations navigates the regulatory pathway in the U.S. while solidifying its presence in international markets. The company’s ability to secure FDA clearance and scale its training programs will be key determinants of its long-term success in the rapidly evolving surgical robotics landscape. For more information, visit the company’s newsroom at https://ibn.fm/SSII.
